GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (ASX:AFP) » Definitions » Capex-to-Revenue

AFT Pharmaceuticals (ASX:AFP) Capex-to-Revenue : 0.06 (As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

AFT Pharmaceuticals's Capital Expenditure for the six months ended in Sep. 2023 was A$-4.47 Mil. Its Revenue for the six months ended in Sep. 2023 was A$76.59 Mil.

Hence, AFT Pharmaceuticals's Capex-to-Revenue for the six months ended in Sep. 2023 was 0.06.


AFT Pharmaceuticals Capex-to-Revenue Historical Data

The historical data trend for AFT Pharmaceuticals's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Capex-to-Revenue Chart

AFT Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capex-to-Revenue
Get a 7-Day Free Trial 0.04 0.06 0.06 0.04 0.06

AFT Pharmaceuticals Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.07 0.05 0.06

Competitive Comparison of AFT Pharmaceuticals's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AFT Pharmaceuticals's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Capex-to-Revenue falls into.



AFT Pharmaceuticals Capex-to-Revenue Calculation

AFT Pharmaceuticals's Capex-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-8.533) / 144.89
=0.06

AFT Pharmaceuticals's Capex-to-Revenue for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-4.471) / 76.59
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AFT Pharmaceuticals  (ASX:AFP) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


AFT Pharmaceuticals Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AFT Pharmaceuticals (ASX:AFP) Business Description

Traded in Other Exchanges
Address
129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.

AFT Pharmaceuticals (ASX:AFP) Headlines

No Headlines